Sodium alginate compositions in the treatment of reflux disease

Enzymatic modification of low G-content alginate using AlgE6R1 enzyme enhances G content and alters M-G block composition, achieving high raft strength and low viscosity, addressing the limitations of natural alginates for GERD treatment and expanding seaweed utilization.

WO2026109548A1PCT designated stage Publication Date: 2026-05-28INT N&H DENMARK APS +1
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
INT N&H DENMARK APS
Filing Date
2025-11-19
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Existing seaweed-extracted alginates with low guluronic acid (G) content are unsuitable for gastroesophageal reflux disease (GERD) treatment, as they fail to meet the British Pharmacopoeia's requirements for raft strength and viscosity, limiting the range of available raw materials and necessitating the utilization of specific seaweed parts.

Method used

Enzymatic modification of low G-content alginate using a modified AlgE6R1 enzyme to increase G content and alter M-G block composition, followed by hydrolysis, precipitation, washing, and neutralization to produce alginate with high G content and low viscosity, suitable for GERD treatment.

Benefits of technology

The enzymatically modified alginate achieves raft strengths above 7.5 g with low viscosity, overcoming the limitations of natural alginates, enabling effective GERD treatment and utilizing a broader range of seaweed biomass.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2025083486_28052026_PF_FP_ABST
    Figure EP2025083486_28052026_PF_FP_ABST
Patent Text Reader

Abstract

The invention described herein include the conversion of alginate that do not have the required mechanical and chemical properties for their use as alginate raft-forming oral suspension (AROS) for Gastroesophageal reflux disease (GERD) therapy into compliant alginate polysaccharides for AROS. The invention consists of the reaction of an epimerase enzyme with alginate polysaccharides containing a high amount of β-D-mannuronic acid sugars in their backbone to obtain alginate polysaccharide with high α-L-guluronic acid content. The reaction of the AlgE6R enzyme converts mannuronic sugars into guluronic sugars by creating long sequence of guluronic sugars increasing the blockiness of the resulting alginate. The invention combines the enzymatic treatment with a hydrolysis step to obtain alginate solutions that not only forms strong hydrogel but exhibit low viscosity in raft formulation offering the possibility to provide a better swallowability for GERD patients.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Compositions and methods for increased protein production in bacillus licheniformis

    EP3585910A1

  • Methods and compositions for efficient genetic modifications of Bacillus licheniformis strains

    US11879127B2

  • Modified Alginates, Methods of Production and Use

    US20080199914A1